Storm Therapeutics closed a $56 million Series C to drive STC-15 into Phase 2 testing across selected sarcoma indications. The RNA-modifying enzyme inhibitor targets METTL3, aiming to disrupt methylation of messenger RNA programs linked to malignant cell survival. Storm said Phase 2 will evaluate STC-15 for safety and efficacy and expects Phase 2 readouts across multiple indications, with the potential to support accelerated approval pathways. The company also pointed to Phase 1 data (NCT0558411) showing durable tumor regression across sarcoma subtypes. University of Miami Sylvester Comprehensive Cancer Center researchers backed the rationale, highlighting METTL3-driven methylation as a sarcoma vulnerability given limited responsiveness to many existing targeted and immunotherapy options.